Health

Eleva Secures up to EUR 60 million to Advance a Drug Candidate, Appoints New Board Member

Eleva, a manufacturer of superior biologics, has secured up to EUR 60 million in funding from Zukunftsfonds Heilbronn (ZFHN). The funds will help advance one of its drug candidates, CPV-101, to stages that will facilitate further investment from venture capitalists and/or pharmaceutical companies. Eleva also announced the addition of Dr. Ralf Smit to its Executive […]

thaipr.net

6 ม.ค. 64

Gift of Life Donor Program Leads U.S. in Organ Donation for 13th Consecutive Year

Region Demonstrates Extraordinary Generosity and Clinical Leadership Despite Pandemic Challenges: Most Organ Donors Every Year Since 2008 For the 13th consecutive year, Gift of Life Donor Program leads the nation in the most organ donors among all 58 U.S. Organ Procurement Organizations (OPO). Thanks to the extraordinary generosity of its community, Gift of Life has coordinated the most organ […]

thaipr.net

6 ม.ค. 64

Bayer and the National Heart Centre Singapore Collaborate to Set Up Center of Excellence for Explorative Cardiovascular Studies

Leveraging on Asian patient data, the 5-year collaboration aims to boost patient-centricity in R&D, leading to improved treatment outcomes in cardiovascular disease (CVD) management. The Center will generate and integrate high quality patient data into early clinical research to inform future targeted therapies for CVDs. Bayer will contribute S$5.4million (approx. EUR 3.4 million) towards this […]

thaipr.net

5 ม.ค. 64

RedHill’s Phase 2/3 COVID-19 Study of Opaganib Passes Second DSMB with Unanimous Recommendation to Continue

Independent DSMB unanimously recommends continuation of the global Phase 2/3 study of orally-administered opaganib in severe COVID-19 based on review of unblinded safety data from 155 treated patients Top-line data from the 270-patient global Phase 2/3 COVID-19 study expected Q1/2021 Top-line data from the 40-patient U.S. Phase 2 study of opaganib in severe COVID-19 expected […]

thaipr.net

23 ธ.ค. 63

Occlutech’s Atrial Flow Regulator (AFR) Receives U.S. FDA Breakthrough Device Designation

Occlutech, a privately-held company, announced today that the US Food and Drug Administration (FDA) has granted the company a Breakthrough Device designation for its first-in-class, implantable Atrial Flow Regulator (AFR) for Pulmonary Arterial Hypertension (PAH). PAH affects hundreds of thousands in the U.S. and globally and is resulting from changes in cells that causes damages […]

thaipr.net

21 ธ.ค. 63

Small vessels can cause big problems; MagicTouch SCB Granted ‘Breakthrough Device Designation’ for the treatment of Small Coronary Artery Lesions

Concept Medical Inc. (CMI) has been granted “Breakthrough Device Designation” from the Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) for the MagicTouch SCB Sirolimus Coated Balloon Catheter, for the treatment of small coronary artery lesions in Coronary Artery Disease (CAD). The proposed indication for use includes “The MagicTouch SCB Sirolimus Coated Balloon Catheter […]

thaipr.net

18 ธ.ค. 63

RedHill’s Phase 2/3 COVID-19 Candidate Opaganib Reduces ARDS-Related Blood Clotting in Preclinical Model

Acute respiratory distress syndrome (ARDS)-induced thrombosis (blood clotting) may occur in up to one-third of COVID-19 patients requiring ICU admission and is a contributing cause of mortality Opaganib demonstrated reduced thrombosis in a preclinical model of ARDS Opaganib has also been shown to inhibit SARS-CoV-2 viral replication as well as pro-inflammatory markers in relevant preclinical […]

thaipr.net

18 ธ.ค. 63
1 … 121 122 123 124 125 … 127

Copyright © 2025 Dataxet Limited (บริษัท ดาต้าเซ็ต จำกัด). All Rights Reserved.